Add time:07/24/2019         Source:sciencedirect.com

BackgroundIn-stent restenosis, or renarrowing within a coronary stent, is the most ominous complication of percutaneous coronary intervention, caused by vascular smooth muscle cell (VSMC) migration into and proliferation in the intima. Although drug-eluting stents reduce restenosis, they delay the tissue healing of the injured arteries. No promising alternative anti-restenosis treatments are currently on the horizon.

We also recommend Trading Suppliers and Manufacturers of morelloflavone (cas 16851-21-1). Pls Click Website Link as below: cas 16851-21-1 suppliers